JP2011509296A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011509296A5 JP2011509296A5 JP2010542280A JP2010542280A JP2011509296A5 JP 2011509296 A5 JP2011509296 A5 JP 2011509296A5 JP 2010542280 A JP2010542280 A JP 2010542280A JP 2010542280 A JP2010542280 A JP 2010542280A JP 2011509296 A5 JP2011509296 A5 JP 2011509296A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- salt
- carboxylic acid
- amide
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 131
- 150000003839 salts Chemical class 0.000 claims description 78
- 230000000155 isotopic effect Effects 0.000 claims description 39
- 208000004296 neuralgia Diseases 0.000 claims description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 27
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 22
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 19
- 208000002193 Pain Diseases 0.000 claims description 18
- -1 pyranopyridyl Chemical group 0.000 claims description 16
- 150000002431 hydrogen Chemical class 0.000 claims description 15
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 14
- 230000036407 pain Effects 0.000 claims description 13
- 125000001475 halogen functional group Chemical group 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 208000037765 diseases and disorders Diseases 0.000 claims description 9
- 230000001404 mediated effect Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 201000004384 Alopecia Diseases 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 206010015037 epilepsy Diseases 0.000 claims description 6
- 208000021722 neuropathic pain Diseases 0.000 claims description 6
- 206010019233 Headaches Diseases 0.000 claims description 5
- 208000019695 Migraine disease Diseases 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 206010027599 migraine Diseases 0.000 claims description 5
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- 208000004371 toothache Diseases 0.000 claims description 5
- 208000003251 Pruritus Diseases 0.000 claims description 4
- 206010043269 Tension headache Diseases 0.000 claims description 4
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 4
- 206010046543 Urinary incontinence Diseases 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 231100000869 headache Toxicity 0.000 claims description 4
- 230000000968 intestinal effect Effects 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 208000000094 Chronic Pain Diseases 0.000 claims description 3
- 208000006561 Cluster Headache Diseases 0.000 claims description 3
- 208000030814 Eating disease Diseases 0.000 claims description 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 206010026749 Mania Diseases 0.000 claims description 3
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 201000009961 allergic asthma Diseases 0.000 claims description 3
- 201000010105 allergic rhinitis Diseases 0.000 claims description 3
- 231100000360 alopecia Toxicity 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 3
- 235000014632 disordered eating Nutrition 0.000 claims description 3
- 206010014599 encephalitis Diseases 0.000 claims description 3
- 208000024963 hair loss Diseases 0.000 claims description 3
- 230000003676 hair loss Effects 0.000 claims description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 230000003959 neuroinflammation Effects 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 3
- 208000036273 reactive airway disease Diseases 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 208000019116 sleep disease Diseases 0.000 claims description 3
- 208000020431 spinal cord injury Diseases 0.000 claims description 3
- 230000009529 traumatic brain injury Effects 0.000 claims description 3
- JAOMTMOEENMHSO-LCNBYPMKSA-N (2r)-6-tert-butyl-n-[1-(1h-indazol-5-yl)ethyl]-2,3-dihydro-1,4-benzodioxine-2-carboxamide Chemical compound C1=C2NN=CC2=CC(C(NC(=O)[C@@H]2OC3=CC=C(C=C3OC2)C(C)(C)C)C)=C1 JAOMTMOEENMHSO-LCNBYPMKSA-N 0.000 claims description 2
- XEHWOBFQEUQOJG-MRXNPFEDSA-N (2r)-n-(7,8-dihydro-5h-pyrano[4,3-b]pyridin-3-yl)-6-(trifluoromethyl)-2,3-dihydro-1,4-benzodioxine-2-carboxamide Chemical compound C1COCC2=CC(NC(=O)[C@@H]3OC4=CC=C(C=C4OC3)C(F)(F)F)=CN=C21 XEHWOBFQEUQOJG-MRXNPFEDSA-N 0.000 claims description 2
- ULYFMTUBYDCUSO-BMLIUANNSA-N (2r)-n-[(1r)-1-(1h-indazol-5-yl)ethyl]-6-(trifluoromethyl)-2,3-dihydro-1,4-benzodioxine-2-carboxamide Chemical compound C1=C2NN=CC2=CC([C@H](NC(=O)[C@@H]2OC3=CC=C(C=C3OC2)C(F)(F)F)C)=C1 ULYFMTUBYDCUSO-BMLIUANNSA-N 0.000 claims description 2
- ULYFMTUBYDCUSO-NPMYUJNRSA-N (2r)-n-[1-(1h-indazol-5-yl)ethyl]-6-(trifluoromethyl)-2,3-dihydro-1,4-benzodioxine-2-carboxamide Chemical compound C1=C2NN=CC2=CC(C(NC(=O)[C@@H]2OC3=CC=C(C=C3OC2)C(F)(F)F)C)=C1 ULYFMTUBYDCUSO-NPMYUJNRSA-N 0.000 claims description 2
- FZMAUNNHDLFMRY-CYBMUJFWSA-N (2r)-n-[2-(hydroxymethyl)-[1,3]thiazolo[5,4-b]pyridin-6-yl]-6-(trifluoromethyl)-2,3-dihydro-1,4-benzodioxine-2-carboxamide Chemical compound C1OC2=CC(C(F)(F)F)=CC=C2O[C@H]1C(=O)NC1=CN=C(SC(CO)=N2)C2=C1 FZMAUNNHDLFMRY-CYBMUJFWSA-N 0.000 claims description 2
- JAOMTMOEENMHSO-JDOQCHFPSA-N (2s)-6-tert-butyl-n-[1-(1h-indazol-5-yl)ethyl]-2,3-dihydro-1,4-benzodioxine-2-carboxamide Chemical compound C1=C2NN=CC2=CC(C(NC(=O)[C@H]2OC3=CC=C(C=C3OC2)C(C)(C)C)C)=C1 JAOMTMOEENMHSO-JDOQCHFPSA-N 0.000 claims description 2
- ULYFMTUBYDCUSO-QGHHPUGFSA-N (2s)-n-[(1r)-1-(1h-indazol-5-yl)ethyl]-6-(trifluoromethyl)-2,3-dihydro-1,4-benzodioxine-2-carboxamide Chemical compound C1=C2NN=CC2=CC([C@H](NC(=O)[C@H]2OC3=CC=C(C=C3OC2)C(F)(F)F)C)=C1 ULYFMTUBYDCUSO-QGHHPUGFSA-N 0.000 claims description 2
- ULYFMTUBYDCUSO-LKDXBUKQSA-N (2s)-n-[1-(1h-indazol-5-yl)ethyl]-6-(trifluoromethyl)-2,3-dihydro-1,4-benzodioxine-2-carboxamide Chemical compound C1=C2NN=CC2=CC(C(NC(=O)[C@H]2OC3=CC=C(C=C3OC2)C(F)(F)F)C)=C1 ULYFMTUBYDCUSO-LKDXBUKQSA-N 0.000 claims description 2
- FLEJYPCTXQXVGM-QGZVFWFLSA-N (6r)-n-(1-acetyl-2,3-dihydroindol-6-yl)-2-(1,1,1-trifluoro-2-methylpropan-2-yl)-5,6,7,8-tetrahydroquinoline-6-carboxamide Chemical compound C1CC2=NC(C(C)(C)C(F)(F)F)=CC=C2C[C@@H]1C(=O)NC1=CC=C2CCN(C(=O)C)C2=C1 FLEJYPCTXQXVGM-QGZVFWFLSA-N 0.000 claims description 2
- IYQOKTWXBNLVCM-CQSZACIVSA-N (6r)-n-(7,8-dihydro-5h-pyrano[4,3-b]pyridin-3-yl)-2-(1,1,1-trifluoro-2-methylpropan-2-yl)-5,6,7,8-tetrahydroquinoline-6-carboxamide Chemical compound C1COCC2=CC(NC(=O)[C@H]3CC4=CC=C(N=C4CC3)C(C)(C)C(F)(F)F)=CN=C21 IYQOKTWXBNLVCM-CQSZACIVSA-N 0.000 claims description 2
- XZKCXBBJLLWZPA-CZUORRHYSA-N (6r)-n-[(1r)-1-(1h-indazol-5-yl)ethyl]-2-(1,1,1-trifluoro-2-methylpropan-2-yl)-5,6,7,8-tetrahydroquinoline-6-carboxamide Chemical compound C1=C2NN=CC2=CC([C@H](NC(=O)[C@H]2CC3=CC=C(N=C3CC2)C(C)(C)C(F)(F)F)C)=C1 XZKCXBBJLLWZPA-CZUORRHYSA-N 0.000 claims description 2
- YLINWODPMYUYFY-UKRRQHHQSA-N (6r)-n-[(1r)-1-(6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazin-3-yl)ethyl]-2-(1,1,1-trifluoro-2-methylpropan-2-yl)-5,6,7,8-tetrahydroquinoline-6-carboxamide Chemical compound C1=NN2CCCOC2=C1[C@@H](C)NC(=O)[C@H]1CC2=CC=C(C(C)(C)C(F)(F)F)N=C2CC1 YLINWODPMYUYFY-UKRRQHHQSA-N 0.000 claims description 2
- HYUBIWOVJYNOHH-GFCCVEGCSA-N (6r)-n-[2-(hydroxymethyl)-[1,3]thiazolo[5,4-b]pyridin-6-yl]-2-(1,1,1-trifluoro-2-methylpropan-2-yl)-5,6,7,8-tetrahydroquinoline-6-carboxamide Chemical compound N1=C2SC(CO)=NC2=CC(NC(=O)[C@H]2CC3=CC=C(N=C3CC2)C(C)(C)C(F)(F)F)=C1 HYUBIWOVJYNOHH-GFCCVEGCSA-N 0.000 claims description 2
- NARBZYHCDKQIGF-MRXNPFEDSA-N (6r)-n-quinolin-3-yl-2-(1,1,1-trifluoro-2-methylpropan-2-yl)-5,6,7,8-tetrahydroquinoline-6-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)[C@H]3CC4=CC=C(N=C4CC3)C(C)(C)C(F)(F)F)=CN=C21 NARBZYHCDKQIGF-MRXNPFEDSA-N 0.000 claims description 2
- IYQOKTWXBNLVCM-AWEZNQCLSA-N (6s)-n-(7,8-dihydro-5h-pyrano[4,3-b]pyridin-3-yl)-2-(1,1,1-trifluoro-2-methylpropan-2-yl)-5,6,7,8-tetrahydroquinoline-6-carboxamide Chemical compound C1COCC2=CC(NC(=O)[C@@H]3CC4=CC=C(N=C4CC3)C(C)(C)C(F)(F)F)=CN=C21 IYQOKTWXBNLVCM-AWEZNQCLSA-N 0.000 claims description 2
- XZKCXBBJLLWZPA-CJNGLKHVSA-N (6s)-n-[(1r)-1-(1h-indazol-5-yl)ethyl]-2-(1,1,1-trifluoro-2-methylpropan-2-yl)-5,6,7,8-tetrahydroquinoline-6-carboxamide Chemical compound C1=C2NN=CC2=CC([C@H](NC(=O)[C@@H]2CC3=CC=C(N=C3CC2)C(C)(C)C(F)(F)F)C)=C1 XZKCXBBJLLWZPA-CJNGLKHVSA-N 0.000 claims description 2
- YLINWODPMYUYFY-HIFRSBDPSA-N (6s)-n-[(1r)-1-(6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazin-3-yl)ethyl]-2-(1,1,1-trifluoro-2-methylpropan-2-yl)-5,6,7,8-tetrahydroquinoline-6-carboxamide Chemical compound C1=NN2CCCOC2=C1[C@@H](C)NC(=O)[C@@H]1CC2=CC=C(C(C)(C)C(F)(F)F)N=C2CC1 YLINWODPMYUYFY-HIFRSBDPSA-N 0.000 claims description 2
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 claims description 2
- WQCHHKJQPPFWNC-UHFFFAOYSA-N 6-bromo-n-(quinolin-4-ylmethyl)-2h-chromene-3-carboxamide Chemical compound C1=CC=C2C(CNC(=O)C=3COC4=CC=C(C=C4C=3)Br)=CC=NC2=C1 WQCHHKJQPPFWNC-UHFFFAOYSA-N 0.000 claims description 2
- AXDHXGLDUPRRGC-UHFFFAOYSA-N 6-chloro-n-(quinolin-4-ylmethyl)-2h-chromene-3-carboxamide Chemical compound C1=CC=C2C(CNC(=O)C=3COC4=CC=C(C=C4C=3)Cl)=CC=NC2=C1 AXDHXGLDUPRRGC-UHFFFAOYSA-N 0.000 claims description 2
- APMBLEGLOBNCDK-UHFFFAOYSA-N 6-chloro-n-[1-(1h-indazol-5-yl)ethyl]-2h-chromene-3-carboxamide Chemical compound C1=C2NN=CC2=CC(C(NC(=O)C=2COC3=CC=C(Cl)C=C3C=2)C)=C1 APMBLEGLOBNCDK-UHFFFAOYSA-N 0.000 claims description 2
- DXZGHUOVWXZODS-UHFFFAOYSA-N 6-tert-butyl-n-(quinolin-4-ylmethyl)-2,3-dihydro-1,4-benzodioxine-2-carboxamide Chemical compound C1=CC=C2C(CNC(=O)C3OC4=CC=C(C=C4OC3)C(C)(C)C)=CC=NC2=C1 DXZGHUOVWXZODS-UHFFFAOYSA-N 0.000 claims description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 claims description 2
- 208000034347 Faecal incontinence Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 2
- WFIHKLWVLPBMIQ-UHFFFAOYSA-N [1,3]thiazolo[5,4-b]pyridine Chemical compound C1=CN=C2SC=NC2=C1 WFIHKLWVLPBMIQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 208000028329 epileptic seizure Diseases 0.000 claims description 2
- 230000009610 hypersensitivity Effects 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 230000007803 itching Effects 0.000 claims description 2
- JJHKSKGUPPBMKG-UHFFFAOYSA-N n-(quinolin-4-ylmethyl)-6-(trifluoromethoxy)-2h-chromene-3-carboxamide Chemical compound C1=CC=C2C(CNC(=O)C=3COC4=CC=C(C=C4C=3)OC(F)(F)F)=CC=NC2=C1 JJHKSKGUPPBMKG-UHFFFAOYSA-N 0.000 claims description 2
- XZKCXBBJLLWZPA-UHFFFAOYSA-N n-[1-(1h-indazol-5-yl)ethyl]-2-(1,1,1-trifluoro-2-methylpropan-2-yl)-5,6,7,8-tetrahydroquinoline-6-carboxamide Chemical compound C1=C2NN=CC2=CC(C(NC(=O)C2CC3=CC=C(N=C3CC2)C(C)(C)C(F)(F)F)C)=C1 XZKCXBBJLLWZPA-UHFFFAOYSA-N 0.000 claims description 2
- ITLAGPPXUHLVNU-UHFFFAOYSA-N n-[1-(1h-indazol-5-yl)ethyl]-4-methyl-6-(trifluoromethyl)-2,3-dihydro-1,4-benzoxazine-2-carboxamide Chemical compound C1=C2NN=CC2=CC(C(NC(=O)C2OC3=CC=C(C=C3N(C)C2)C(F)(F)F)C)=C1 ITLAGPPXUHLVNU-UHFFFAOYSA-N 0.000 claims description 2
- HXCCHLPVIPAPNC-UHFFFAOYSA-N n-[2-(hydroxymethyl)-[1,3]thiazolo[5,4-b]pyridin-6-yl]-6-methyl-2-(1,1,1-trifluoro-2-methylpropan-2-yl)-7,8-dihydro-5h-quinoline-6-carboxamide Chemical compound N1=C2SC(CO)=NC2=CC(NC(=O)C2(C)CC3=CC=C(N=C3CC2)C(C)(C)C(F)(F)F)=C1 HXCCHLPVIPAPNC-UHFFFAOYSA-N 0.000 claims description 2
- 210000002345 respiratory system Anatomy 0.000 claims description 2
- IYUQXDINFWPHID-UHFFFAOYSA-N 6-tert-butyl-n-[2-(hydroxymethyl)-[1,3]thiazolo[5,4-b]pyridin-6-yl]-2,3-dihydro-1,4-benzodioxine-3-carboxamide Chemical compound N1=C2SC(CO)=NC2=CC(NC(=O)C2COC3=CC=C(C=C3O2)C(C)(C)C)=C1 IYUQXDINFWPHID-UHFFFAOYSA-N 0.000 claims 1
- 206010061481 Renal injury Diseases 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 208000037806 kidney injury Diseases 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 16
- 208000024891 symptom Diseases 0.000 description 13
- 206010029240 Neuritis Diseases 0.000 description 10
- 230000007794 irritation Effects 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 6
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 208000023504 respiratory system disease Diseases 0.000 description 3
- 206010003399 Arthropod bite Diseases 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- 208000001387 Causalgia Diseases 0.000 description 2
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 2
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
- 206010065390 Inflammatory pain Diseases 0.000 description 2
- 208000006877 Insect Bites and Stings Diseases 0.000 description 2
- 206010049949 Intercostal neuralgia Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
- 206010068106 Occipital neuralgia Diseases 0.000 description 2
- 208000004983 Phantom Limb Diseases 0.000 description 2
- 206010056238 Phantom pain Diseases 0.000 description 2
- 206010036105 Polyneuropathy Diseases 0.000 description 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 2
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 2
- 208000008765 Sciatica Diseases 0.000 description 2
- 208000004078 Snake Bites Diseases 0.000 description 2
- 208000003589 Spider Bites Diseases 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 230000007885 bronchoconstriction Effects 0.000 description 2
- 229960002504 capsaicin Drugs 0.000 description 2
- 235000017663 capsaicin Nutrition 0.000 description 2
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 201000005442 glossopharyngeal neuralgia Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 201000009985 neuronitis Diseases 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 210000003254 palate Anatomy 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- IMACFCSSMIZSPP-UHFFFAOYSA-N phenacyl chloride Chemical compound ClCC(=O)C1=CC=CC=C1 IMACFCSSMIZSPP-UHFFFAOYSA-N 0.000 description 2
- 208000019629 polyneuritis Diseases 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000003491 tear gas Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 description 2
- FVVKBBUWVDYDTB-UHFFFAOYSA-N (6-amino-[1,3]thiazolo[5,4-b]pyridin-2-yl)methanol Chemical compound NC1=CN=C2SC(CO)=NC2=C1 FVVKBBUWVDYDTB-UHFFFAOYSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- 208000002472 Morton Neuroma Diseases 0.000 description 1
- 208000020059 Morton neuralgia Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 208000012790 cranial neuralgia Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 208000020629 overactive bladder Diseases 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 210000001738 temporomandibular joint Anatomy 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1054208P | 2008-01-09 | 2008-01-09 | |
| US12424008P | 2008-04-14 | 2008-04-14 | |
| PCT/US2009/000150 WO2009089057A1 (en) | 2008-01-09 | 2009-01-09 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011509296A JP2011509296A (ja) | 2011-03-24 |
| JP2011509296A5 true JP2011509296A5 (enExample) | 2013-01-10 |
Family
ID=40434003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010542280A Withdrawn JP2011509296A (ja) | 2008-01-09 | 2009-01-09 | イオンチャネルリガンドとしてのアミド誘導体およびそれを使用する薬学的組成物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US8163901B2 (enExample) |
| EP (1) | EP2240467B1 (enExample) |
| JP (1) | JP2011509296A (enExample) |
| CA (1) | CA2707441A1 (enExample) |
| WO (1) | WO2009089057A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2382197B1 (en) | 2008-12-30 | 2016-10-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP2447263A1 (en) | 2010-09-27 | 2012-05-02 | Bioprojet | Benzazole derivatives as histamine H4 receptor ligands |
| RU2724350C1 (ru) | 2017-03-13 | 2020-06-23 | Раквалиа Фарма Инк. | Производные тетрагидрохинолина в качестве антагонистов рецептора р2х7 |
| TWI878266B (zh) | 2019-02-15 | 2025-04-01 | 愛爾蘭商博士倫愛爾蘭有限公司 | 治療眼表痛之方法 |
| JP6994061B2 (ja) | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2526387A1 (en) | 2003-06-12 | 2004-12-23 | Astellas Pharma Inc. | Benzamide derivative or salt thereof |
| FR2880625B1 (fr) | 2005-01-07 | 2007-03-09 | Sanofi Aventis Sa | Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| WO2007109160A2 (en) * | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| WO2007133637A2 (en) | 2006-05-10 | 2007-11-22 | Renovis, Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| EP2044018A1 (en) * | 2006-07-11 | 2009-04-08 | Pfizer Japan, Inc. | Substituted n-bicyclicalkyl bicyclic carboxyamide compounds |
| WO2008090434A1 (en) * | 2007-01-25 | 2008-07-31 | Pfizer Japan Inc. | Substituted n-bicyclicalkyl bicyclic carboxyamide compounds |
-
2009
- 2009-01-09 CA CA2707441A patent/CA2707441A1/en not_active Abandoned
- 2009-01-09 EP EP09700264A patent/EP2240467B1/en not_active Not-in-force
- 2009-01-09 WO PCT/US2009/000150 patent/WO2009089057A1/en not_active Ceased
- 2009-01-09 US US12/811,972 patent/US8163901B2/en not_active Expired - Fee Related
- 2009-01-09 JP JP2010542280A patent/JP2011509296A/ja not_active Withdrawn
-
2012
- 2012-04-20 US US13/452,443 patent/US20130045973A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7677983B2 (ja) | Ｐｇｄｈ阻害剤、およびその作製と使用の方法 | |
| JP2008546639A5 (enExample) | ||
| CN1659144B (zh) | 喹啉和异喹啉衍生物、其制备方法以及作为炎症抑制剂的应用 | |
| CA2733247C (en) | Heterocyclic amide derivatives as ep4 receptor antagonists | |
| CN1056611C (zh) | 吡唑并吡啶和吡咯并吡啶,其用途和用于制备它们的中间体 | |
| JP5733982B2 (ja) | サイトカインの産生を抑制する化合物及びその調製方法 | |
| JP5813626B2 (ja) | 新規抗炎症剤 | |
| JP4671123B2 (ja) | 新規三環性複素環化合物 | |
| JP2010524930A5 (enExample) | ||
| JP2007509043A5 (enExample) | ||
| JP2011509296A5 (enExample) | ||
| JP2011503072A5 (enExample) | ||
| WO2005040114A1 (en) | Compounds having crth2 antagonist activity | |
| JP2007008816A (ja) | 新規イソキノリン誘導体 | |
| JP2021518388A (ja) | オキサジアゾール一過性受容器電位チャネル阻害剤 | |
| JP2011514894A5 (enExample) | ||
| TW200628472A (en) | Piperidinylamino-thieno (2,3-d) pyrimidine compounds | |
| JP2007536374A (ja) | ヒスタミンｈ３受容体リガンドとして有用なテトラヒドロナフチリヂン誘導体 | |
| WO1993009116A1 (fr) | Compose a base de quinuclidine et utilisation dudit compose en medecine | |
| CN1227233C (zh) | 纯晶形的5－氯－3－(4－甲磺酰基苯基)－6′－甲基－[2,3′]联吡啶及其合成方法 | |
| AU2022307534B2 (en) | Pyridinone mk2 inhibitors and uses thereof | |
| KR20140054246A (ko) | 키나제 억제제로서의 아미노 퀴나졸린 | |
| JP2010523562A5 (enExample) | ||
| JP2010520875A5 (enExample) | ||
| WO2005035501A1 (ja) | 新規オレフィン誘導体 |